{{Infobox drug
| verifiedrevid = 461113044
| IUPAC_name = (''RR'',''SS'')-''N''-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl) propan-2-ylamino]ethyl] phenyl]formamide
| image = Formoterol.svg
| width = 230
| image2 = Formoterol ball-and-stick model.png
| caption = Formoterol (top),<br />(''R'',''R'')-(−)-formoterol (center) and<br />(''S'',''S'')-(+)-formoterol (bottom)
| chirality = [[Racemic mixture]]

<!-- Clinical data -->
| tradename = See below
| Drugs.com = {{drugs.com|monograph|foradil}}
| pregnancy_AU = B3
| pregnancy_US = C
| legal_AU =  
| legal_CA =  
| legal_UK = POM
| legal_US = Rx-only
| legal_status = Rx-only
| routes_of_administration = Inhalation ([[Capsule (pharmacy)|capsules]] for oral inhalation, [[Dry powder inhaler|DPI]], [[Metered-dose inhaler|MDI]])

<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound = 61–64%
| metabolism = [[Liver|Hepatic]] [[demethylation]] and [[glucuronidation]] ([[CYP2D6]], [[CYP2C19]], [[CYP2C9]] and [[CYP2A6]] involved)
| elimination_half-life = 10 hours
| excretion = [[Kidney|Renal]] and fecal

<!-- Identifiers -->
| index_label =
| index2_label =
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 73573-87-2
| ATC_prefix = R03
| ATC_suffix = AC13
| ATC_supplemental =  
| PubChem = 3083544
| PubChem2 = 3034756
| IUPHAR_ligand = 3465
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00983
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2340731
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5ZZ84GCW8B
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07990
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 408174
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1363

<!-- Chemical data -->
| C=19 | H=24 | N=2 | O=4
| molecular_weight = 344.405 g/mol
| smiles = O=CNc1cc(ccc1O)[C@@H](O)CN[C@H](C)Cc2ccc(OC)cc2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BPZSYCZIITTYBL-YJYMSZOUSA-N
}}

'''Formoterol''' ([[International Nonproprietary Name|INN]]) or '''eformoterol''' (former [[British Approved Name|BAN]]) is a [[Long-acting beta-adrenoceptor agonist|long-acting β<sub>2</sub> agonist]] (LABA) used in the management of [[asthma]] and [[Chronic obstructive pulmonary disease|COPD]]. It is marketed in three forms: a [[dry-powder inhaler]], a [[metered-dose inhaler]] and an inhalation solution, under various trade names including '''Atock''', '''Atimos'''/'''Atimos Modulite''', '''Foradil'''/'''Foradile''', Oxeze/'''Oxis''', and '''Perforomist'''.  It is also marketed in the combination formulations [[budesonide/formoterol]] and [[mometasone/formoterol]].

Formoterol has an extended duration of action (up to 12 hours) compared to short-acting β<sub>2</sub> agonists such as [[salbutamol]] (albuterol), which are effective for 4–6 hours. LABAs such as formoterol are used as "symptom controllers" to supplement prophylactic [[corticosteroid]] therapy. A "reliever" short-acting β<sub>2</sub> agonist (e.g., [[salbutamol]]) is still required, since LABAs are not recommended for the treatment of acute asthma.

==Mechanism of action==
Inhaled formoterol works like other [[beta2-adrenergic receptor agonist|β<sub>2</sub> agonist]]s, causing bronchodilation by relaxing the smooth muscle in the airway so as to treat the exacerbation of asthma.

==Safety==
In November 2005, the US [[Food and Drug Administration|FDA]] released a health advisory alerting the public to findings that show the use of long-acting β<sub>2</sub> agonists could lead to a worsening of wheezing symptoms in some patients.<ref>{{cite web | author=Center for Drug Evaluation and Research| work=Postmarket Drug Safety Information for Patients and Providers|title= Advair Diskus, Advair HFA, Brovana, Foradil, Perforomist, Serevent Diskus, and Symbicort Information (Long Acting Beta Agonists)| url=http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm108111.htm}}</ref>

At the current time, available long-acting β<sub>2</sub> agonists include [[salmeterol]], formoterol, [[bambuterol]], and sustained-release oral [[salbutamol]]. 

Combinations of inhaled steroids and long-acting bronchodilators are becoming more widespread – combination preparations include [[fluticasone/salmeterol]] and [[budesonide/formoterol]].

==Additional potential uses==

===β<sub>2</sub> agonists in treatment of obesity===
β<sub>2</sub> agonists increase energy utilization and fat metabolism, however, therapeutic use for [[obesity]] has been limited by the concomitant activation of [[Beta-1 adrenergic receptor|β<sub>1</sub> receptor]]s resulting in excessive increases in heart rate. A recent 2012 dose-finding study (in healthy men) demonstrated significantly increased resting energy expenditure, and fat oxidation at a dose  of 160&nbsp;μg of formoterol per day without significantly increased heart rate. Formoterol's specificity for the β<sub>2</sub> receptor (relative to β<sub>1</sub> receptors) may facilitate its use for this purpose. A combination of a highly selective β<sub>2</sub> agonist like formeterol with a low dose highly selective β<sub>1</sub> blocker may further improve the differential therapeutic ability to selectively agonize β<sub>2</sub> receptors for metabolic benefits in treating obesity without adverse β<sub>1</sub> agonist effects.<ref>{{cite journal | doi=10.1038/ijo.2012.90 | issn=1476-5497 | volume=37 | issue=4 | pages=593–597 | last=Lee | first=P |author2=Day, RO |author3=Greenfield, JR |author4= Ho, KKY  | title=Formoterol, a highly β2-selective agonist, increases energy expenditure and fat utilisation in men | journal=International Journal of Obesity| date=May 29, 2012|pmid=22641064}}</ref>

===Stimulation of mitochondrial biogenesis===
Formoterol may also help stimulate [[mitochondrial biogenesis]]. Mitochondrial dysfunction is related to many degenerative diseases&nbsp;— particularly neurodegenerative disorders.<ref>{{cite journal | doi=10.1124/jpet.112.191528 | issn=1521-0103 | volume=342 | issue=1 | pages=106–118 | last=Wills | first=Lauren P |author2=Trager, Richard E|author3=Beeson, Gyda C|author4=Lindsey, Christopher C|author5=Peterson, Yuri K|author6=Beeson, Craig C|author7= Schnellmann, Rick G | title=The β2-adrenoceptor agonist formoterol stimulates mitochondrial biogenesis | journal=The Journal of Pharmacology and Experimental Therapeutics | date= April 6, 2012|pmc=3383035|pmid=22490378}}</ref>

===Treatment for Down syndrome===
Preliminary research offers hope that formoterol may be a useful treatment in [[Down syndrome]]. In a mouse model of the disease, the drug strengthened nerve connections in the hippocampus, a brain center used for spatial navigation, paying attention and forming new memories.<ref>{{cite journal|last1=Dang|first1=Van|last2=Medina|first2=Brian|last3=Das|first3=Devsmita|last4=Moghadam|first4=Sarah|last5=Martin|first5=Kara J.|last6=Lin|first6=Bill|last7=Naik|first7=Priyanka|last8=Patel|first8=Devan|last9=Nosheny|first9=Rachel|last10=Wesson Ashford|first10=John|last11=Salehi|first11=Ahmad|title=Formoterol, a Long-Acting β<sub>2</sub> Adrenergic Agonist, Improves Cognitive Function and Promotes Dendritic Complexity in a Mouse Model of Down Syndrome|journal=Biological Psychiatry|date=February 2014|volume=75|issue=3|pages=179–188|doi=10.1016/j.biopsych.2013.05.024|pmid=23827853|issn=1873-2402}}<!--|accessdate=14 February 2016--></ref>

==Trade names==
[[File:Budesonide and formoterol inhaler.jpg|thumb|200px|Inhaler for a powder based in [[budesonide]] and formoterol]]
* Foradil/Foradile [[Capsule (pharmacy)|capsules]] for oral inhalation ([[Schering-Plough]] in the U.S., [[Novartis]] rest of world)
* Oxeze/Oxis Turbuhaler [[Dry powder inhaler|DPI]] ([[AstraZeneca]])
* Atock ([[Astellas Pharma|Astellas]])
* Atimos/Atimos Modulite [[Metered-dose inhaler|MDI]] ([[Chiesi Farmaceutici S.p.A.|Chiesi]])
* Perforomist inhalation [[solution]] ([[Mylan|Mylan N.V.]])

==See also==
* [[Arformoterol]] ((''R'',''R'')-(−)-formoterol) — an [[Enantiopure drug|enantiopure]] compound used in the management of [[Chronic obstructive pulmonary disease|COPD]]
* Combination drugs:
** [[Aclidinium/formoterol|Aclidinium bromide/formoterol]]
** [[Budesonide/formoterol]]
** [[Mometasone/formoterol|Mometasone furoate/formoterol]]

==References==
{{reflist}}

{{Asthma and copd rx}}
{{Adrenergic agonists}}

[[Category:Beta2-adrenergic agonists]]
[[Category:Phenol ethers]]
[[Category:Phenols]]
[[Category:Formamides]]
[[Category:Substituted amphetamines]]

[[pnb:آمو دریا]]